Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.
Int J Infect Dis
; 102: 517-523, 2021 Jan.
Article
de En
| MEDLINE
| ID: mdl-33176205
ABSTRACT
OBJECTIVES:
The World Health Organization pre-qualified single-dose typhoid conjugate vaccine (TCV) and requested data on co-administration with routine vaccines. The co-administration of Typbar TCV (Bharat Biotech International) with routine group A meningococcal conjugate vaccine (MCV-A) and measles-rubella (MR) vaccine was tested.METHODS:
This was a double-blind, randomized controlled trial performed in Ouagadougou, Burkina Faso. Children were recruited at the 15-month vaccination visit and were assigned randomly (111) to three groups. Group 1 children received TCV plus control vaccine (inactivated polio vaccine) and MCV-A 28 days later; group 2 children received TCV and MCV-A; group 3 children received MCV-A and control vaccine. Routine MR vaccine was administered to all participants. Safety was assessed at 0, 3, and 7 days after immunization, and unsolicited adverse events and serious adverse events were assessed for 28 days and 6 months after immunization, respectively.RESULTS:
A total of 150 children were recruited and vaccinated. Solicited symptoms were infrequent and similar for TCV and control recipients, as were adverse events (group 1, 61.2%; group 2, 64.0%; group 3, 68.6%) and serious adverse events (group 1, 2.0%; group 2, 8.0%; group 3, 5.9%). TCV generated robust immunity without interference with MCV-A vaccine.CONCLUSIONS:
TCV can be safely co-administered at 15 months with MCV-A without interference. This novel study on the co-administration of TCV with MCV-A provides data to support large-scale uptake in sub-Saharan Africa.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Rubéole
/
Fièvre typhoïde
/
Vaccin contre la rougeole
/
Vaccin antirubéoleux
/
Vaccins antityphoparatyphoïdiques
/
Vaccins antiméningococciques
/
Rougeole
Type d'étude:
Clinical_trials
Limites:
Female
/
Humans
/
Infant
/
Male
Pays/Région comme sujet:
Africa
Langue:
En
Journal:
Int J Infect Dis
Sujet du journal:
DOENCAS TRANSMISSIVEIS
Année:
2021
Type de document:
Article